TY - JOUR
T1 - 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation
AU - Bolaños-Meade, Javier
AU - Smith, B. Douglas
AU - Gore, Steven D.
AU - McDevitt, Michael A.
AU - Luznik, Leo
AU - Fuchs, Ephraim J.
AU - Jones, Richard J.
N1 - Funding Information:
This research was supported in part by the grant P01CA15396 from the National Cancer Institute (Richard J. Jones, MD). Dr. Bolaños-Meade is an Investigator-2 Sistema Nacional de Investigadores (CONACYT, Mexico).
PY - 2011/5
Y1 - 2011/5
N2 - Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.
AB - Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.
KW - 5-Azacytidine
KW - Acute myeloid leukemia
KW - Donor lymphocyte infusion
KW - Graft-versus-host disease
KW - Myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=79954573454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954573454&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2010.10.008
DO - 10.1016/j.bbmt.2010.10.008
M3 - Article
C2 - 20951817
AN - SCOPUS:79954573454
SN - 1083-8791
VL - 17
SP - 754
EP - 758
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -